These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19400935)

  • 1. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
    Yuan ZG; Dun XY; Li YH; Hou J
    J Hematol Oncol; 2009 Apr; 2():19. PubMed ID: 19400935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
    Khan AA; Siraj F; Bhargava M; Aggarwal S
    BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23264156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
    Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
    AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
    Minarik J; Scudla V; Tichy T; Pika T; Bacovsky J; Lochman P; Zadrazil J
    Leuk Lymphoma; 2012 Feb; 53(2):330-1. PubMed ID: 21883030
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
    Szturz P; Adam Z; Vašků V; Feit J; Krejčí M; Pour L; Hájek R; Mayer J
    Leuk Lymphoma; 2013 Jun; 54(6):1324-6. PubMed ID: 23061634
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
    [No Abstract]   [Full Text] [Related]  

  • 7. POEMS syndrome, osteosclerotic myeloma and Castleman's disease: a case report.
    Bosco J; Pathmanathan R
    Aust N Z J Med; 1991 Aug; 21(4):454-6. PubMed ID: 1953537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extramedullary involvement: an emerging problem in multiple myeloma.
    Molica S
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
    [No Abstract]   [Full Text] [Related]  

  • 9. HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.
    Sbenghe MM; Besa E; Mahipal A; Dulau Florea A; Bray P; Caro J
    Oncologist; 2012; 17(1):145-6; author reply 147-8. PubMed ID: 22286773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Follicular keratosis and multiple myeloma].
    García-Romero D; Sanz-Robles H; Arrue I; Sánchez-Largo ME; Rodríguez-Peralto JL; Vanaclocha F
    Actas Dermosifiliogr; 2006 Nov; 97(9):599-602. PubMed ID: 17173767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematology: first-line bortezomib benefits patients with multiple myeloma.
    Dimopoulos MA; Terpos E
    Nat Rev Clin Oncol; 2009 Dec; 6(12):683-5. PubMed ID: 19942924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
    Tanaka T; Yamasaki R; Omura H; Hino N
    Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
    [No Abstract]   [Full Text] [Related]  

  • 13. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.
    Mauermann ML; Blumenreich MS; Dispenzieri A; Staff NP
    Muscle Nerve; 2012 Dec; 46(6):970-7. PubMed ID: 23225391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH; Tsui J; Wang XY; Liu SS; Li J
    Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract]   [Full Text] [Related]  

  • 17. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
    San Miguel JF
    Haematologica; 2014 Jan; 99(1):5-6. PubMed ID: 24425688
    [No Abstract]   [Full Text] [Related]  

  • 20. [Multiple myeloma and intravenous immunoglobulins].
    Feugier P; Tomowiak C; Daguindau N; Perrot A
    Rev Med Interne; 2007 Jun; 28 Spec No 2():5-6. PubMed ID: 17893960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.